Volume 6; Issue 4

Main
The Lancet Haematology
Volume 6; Issue 4

The Lancet Haematology

Volume 6; Issue 4

1

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

Hutchison, Colin A, Cockwell, Paul, Moroz, Veronica, Bradwell, Arthur R, Fifer, Lesley, Gillmore, Julian D, Jesky, Mark D, Storr, Markus, Wessels, Julie, Winearls, Christopher G, Weisel, Katja, Heyne,

Journal:

The Lancet Haematology

Year:

2019

File:

PDF, 1.50 MB

2019

2

Improvements in haploidentical transplantation for sickle cell disease and β-thalassaemia

Journal:

The Lancet Haematology

Year:

2019

File:

PDF, 126 KB

2019

3

10-day vs 5-day decitabine: equivalence cannot be concluded

Huls, Gerwin, Suciu, Stefan, Wijermans, Pierre, Kicinski, Michal, Lübbert, Michael

Journal:

The Lancet Haematology

Year:

2019

File:

PDF, 37 KB

2019

4

Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?

Journal:

The Lancet Haematology

Year:

2019

File:

PDF, 104 KB

2019

5

Can apixaban prevent venous thromboembolism better than rivaroxaban?

Coleman, Craig I, Baker, William L

Journal:

The Lancet Haematology

Year:

2019

File:

PDF, 32 KB

2019

6

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Savona, Michael R, Odenike, Olatoyosi, Amrein, Philip C, Steensma, David P, DeZern, Amy E, Michaelis, Laura C, Faderl, Stefan, Harb, Wael, Kantarjian, Hagop, Lowder, James, Oganesian, Aram, Azab, Moha

Journal:

The Lancet Haematology

Year:

2019

File:

PDF, 468 KB

2019

7

Can apixaban prevent venous thromboembolism better than rivaroxaban?

Akbashev, Mikhail, Adhyaru, Bhavin, Allen, Arthur

Journal:

The Lancet Haematology

Year:

2019

File:

PDF, 39 KB

2019

8

Can apixaban prevent venous thromboembolism better than rivaroxaban? – Authors' reply

Dawwas, Ghadeer K, Brown, Joshua, Dietrich, Eric, Park, Haesuk

Journal:

The Lancet Haematology

Year:

2019

Language:

english

File:

PDF, 40 KB

english, 2019

9

Sickle-cell anaemia—keeping alive Wethers' legacy

The Lancet Haematology,

Journal:

The Lancet Haematology

Year:

2019

Language:

english

File:

PDF, 127 KB

english, 2019

10

10-day vs 5-day decitabine: equivalence cannot be concluded

Huls, Gerwin, Suciu, Stefan, Wijermans, Pierre, Kicinski, Michal, Lübbert, Michael

Journal:

The Lancet Haematology

Year:

2019

Language:

english

File:

PDF, 37 KB

english, 2019

11

Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?

Journal:

The Lancet Haematology

Year:

2019

Language:

english

File:

PDF, 104 KB

english, 2019

12

Can apixaban prevent venous thromboembolism better than rivaroxaban?

Coleman, Craig I, Baker, William L

Journal:

The Lancet Haematology

Year:

2019

Language:

english

File:

PDF, 32 KB

english, 2019

13

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Savona, Michael R, Odenike, Olatoyosi, Amrein, Philip C, Steensma, David P, DeZern, Amy E, Michaelis, Laura C, Faderl, Stefan, Harb, Wael, Kantarjian, Hagop, Lowder, James, Oganesian, Aram, Azab, Moha

Journal:

The Lancet Haematology

Year:

2019

Language:

english

File:

PDF, 468 KB

english, 2019

14

Can apixaban prevent venous thromboembolism better than rivaroxaban?

Akbashev, Mikhail, Adhyaru, Bhavin, Allen, Arthur

Journal:

The Lancet Haematology

Year:

2019

Language:

english

File:

PDF, 39 KB

english, 2019

15

10-day vs 5-day decitabine: equivalence cannot be concluded – Authors' reply

Short, Nicholas J, Ravandi, Farhad

Journal:

The Lancet Haematology

Year:

2019

Language:

english

File:

PDF, 32 KB

english, 2019